Tokuyama Corporation
4043・Prime Market・Chemicals
Business
Tokuyama Corporation is a comprehensive chemical manufacturer founded in 1918, with its core base at the Tokuyama Manufacturing Complex in Shunan City, Yamaguchi Prefecture. The company operates across five segments: Chemical Products (Caustic Soda, Vinyl Chloride, etc.), Cement, Advanced Electronic Materials (Polycrystalline Silicon, Fumed Silica, Aluminum Nitride), Life Science (in-vitro diagnostics, Dental Equipment, lens materials), and Environmental Business (Ion Exchange Membrane, Waste Gypsum Board Recycling). It has 55 subsidiaries and 33 affiliated companies, with overseas manufacturing and sales bases mainly in Asia. Its major customers span semiconductor manufacturers, electronic component manufacturers, medical institutions, and the construction industry, and it recorded net sales of ¥349,476 million (FY2026 (ending March 2026)).
Business Model
Building on the electrolysis and chemical processes at the Tokuyama Plant, the company manufactures and sells a vertically integrated range of products, from basic chemicals such as Caustic Soda to high-value-added electronic materials such as semiconductor-grade Polycrystalline Silicon, IC Chemicals, and Heat-Dissipating Materials. The Cement business is being transferred to Taiheiyo Cement, allowing management resources to be concentrated on the three growth fields of "Electronics," "Health," and "Environment." With R&D expenses of ¥17,706 million and capital expenditures of ¥32,759 million (FY2026 (ending March 2026)), the company adopts a model that converts technological superiority into earnings.
Company Strengths
The Advanced Electronic Materials segment, which is the only company able to supply Polycrystalline Silicon, Fumed Silica, IC Chemicals, and Aluminum Nitride under one roof, achieved net sales of ¥91,675 million and operating income of ¥15,681 million (up 63.6% year on year) in FY2026 (ending March 2026). Through the construction of a new plant in Vietnam and the establishment of a joint venture with the OCI Group of Malaysia, the company is building an international supply system for semiconductor-grade Polycrystalline Silicon.
"Omnichroma®," a dental filling composite resin utilizing structural color developed by Tokuyama Dental, received the Commissioner of the Japan Patent Office Award at the National Invention Awards. The Life Science segment achieved net sales of ¥49,387 million (up 17.7% year on year) in FY2026 (ending March 2026), driven by increased overseas shipments of Dental Equipment. Technological superiority backed by patents underpins the company's competitiveness in overseas expansion.
Since its founding in 1918, the company has internally accumulated manufacturing technologies including the ammonia soda process, electrolytic Caustic Soda, and Polycrystalline Silicon (production started in 1984). These technologies have also been applied to the production of large-scale salt electrolyzers aiming for world-class energy-saving performance and the development of high-pressure AWE, giving the company a proprietary technological foundation that competitors find difficult to replicate in a short period. R&D expenditure amounted to ¥17,706 million in FY2026 (ending March 2026).
ENVALITH's Perspective
Performance Trend
Revenue was ¥349,476 million (up 1.9% year on year), operating profit was ¥37,017 million (up 23.5%), and ordinary profit was ¥38,203 million (up 29.1%), showing significant improvement at the operating and ordinary profit levels. Improved manufacturing costs for Advanced Electronic Materials, solid sales of semiconductor-related products, and the newly consolidated Life Science business contributed to revenue growth. On the other hand, profit attributable to owners of parent was limited to ¥22,205 million (down 5.1%), affected by the recording of an extraordinary loss of ¥3,630 million for provision for contract losses related to a long-term power purchase agreement with a power generation operator, as well as an income tax adjustment impact of ¥8,355 million due to changes in estimates of deferred tax assets. Over the past five fiscal years, following the sharp profit decline in FY2023 (ending March 2023) (operating profit of ¥14,336 million) as the trough, a recovery trend has continued, and operating profit in FY2026 (ending March 2026) reached its highest level in five fiscal years.
Growth Strategy
Accelerating structural transformation through focused investment in the three fields of 'Electronics, Health, and Environment' and resource reallocation via divestiture of the Cement business
Linking the polycrystalline silicon manufacturing and sales facility under construction in Vietnam with OCI Tokuyama Semiconductor Materials Sdn. Bhd., a Malaysia joint venture with South Korea's OCI Group, to establish a production and supply system for semiconductor-grade polycrystalline silicon. A core initiative to capture growing demand for advanced semiconductors.
Consolidated the in-vitro diagnostic reagents/pharmaceuticals business acquired from JSR (acquisition cost ¥80,637 million) from October 2025. Aiming to rapidly build a highly profitable reagent business through cross-selling with A&T Corporation and complementary capabilities for commercializing particle and antibody immunoassay reagents. Goodwill of ¥60,139 million (provisional) to be amortized on a straight-line basis over 20 years.
After transferring the domestic Cement and solidifying materials sales business and shares of certain consolidated subsidiaries to a newly established wholly owned subsidiary, the entity is planned to be transferred to Taiheiyo Cement effective October 1, 2026. Discontinuation of manufacturing operations is under consideration, targeted for FY2028. Proceeds from the transfer will be reallocated to the three growth fields, further accelerating the transformation of the business portfolio.
Promoting commercialization of low-temperature pyrolysis recycling technology through participation in the 'Hokkaido Consortium for Promoting Resource Recycling of Used Solar Panels,' capital participation in H2 Hokkaido Co., Ltd. to develop applications for magnesium hydride, and modification and startup of biomass co-firing facilities. A medium- to long-term initiative toward achieving carbon neutrality by FY2030.
The Medium-Term Management Plan 2025 (final-year results: net sales of ¥349,476 million, operating profit of ¥37,017 million, ROE of 8.2%) concluded without achieving its main targets. The company has stated its policy to focus on growth fields and enhance corporate value under the next medium-term management plan covering FY2026 through FY2030. Specific numerical targets and measures have not yet been disclosed.
Last updated: July 19, 2026